Monoclonal antibodies: Targeted therapy

Indian Journal of Pharmacology

Volumn 38, Issue 6, 2006, Pages 390-396

  Gupta, N ^a   Srivastava, A ^a  

^a Intas Biotechnology/Oncology   (India)

Author keywords

Antibodies; Chemotherapy; Immunity; Malignancy

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; ANGIOGENESIS INHIBITOR; BASILIXIMAB; BEVACIZUMAB; CALICHEAMICIN; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EPRATUZUMAB; FOLINIC ACID; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INDIUM 111; INFLIXIMAB; IODINE 131; IRINOTECAN; MONOCLONAL ANTIBODY; OKT 3; OMALIZUMAB; OXALIPLATIN; PALIVIZUMAB; PERTUZUMAB; PROTEASOME INHIBITOR; PROTEIN KINASE INHIBITOR; RITUXIMAB; TOSITUMOMAB; TRASTUZUMAB; UNINDEXED DRUG; YTTRIUM 90;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; ASTHMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; DERMATOMYOSITIS; DRUG INDICATION; DRUG TARGETING; DRUG TOLERABILITY; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER METASTASIS; MONOTHERAPY; NEPHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL DESTRUCTION; VIRUS INFECTION;

EID: 33845268631     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.28204     Document Type: Review

References (33)

1. Multani PS, Grossbard ML. Monoclonal antibody-based therapies for hematological malignancies. J Clin Oncol 1998;16:3691-710.
2. White CA, Weaver RL, Antonio J, Grillo- Lopez. Antibody- targeted immunotherapy for treatment of malignancy. Ann Rev Med 2001;52:125-45.
3. Kosmos C, Stamatopoulos K, Stavroyianni N, Savaris N and Papadaki T. Anti-CD20- based therapy of B cell lymphoma: state of the art. Leukemia 2002;16:2004-5.
4. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: Ongoing and future clinical development. Semin Oncol 2002;29:105-12.
5. John CB. Monoclonal antibody therapy for hematologic malignancies: Introduction. Semin Oncol 2003;30:421-3.
6. Montserrat E. Rituximab in chronic lymphocytic leukemia. Semin Oncol 2003;30:34-9.
7. Dillman RO. Treatment of low grade B- cell lymphoma with the monoclonal antibody rituximab. Semin Oncol 2003;30:434-47.
8. Czuczman MS, Grillo-Lpoz AJ, White CJ, Saleh M, Gordon L, LoBuglio, et al. Treatment of patients with low grade B- Cell Lymphoma with the combination of chimeric Anti-CD20 monoclonal antibody and CHOP Chemotherapy. J Clin Oncol 1999;17:268-76.
9. Garcia-Conde J, Conde E , Sierra J, Caballero D, Arranz R, Leon A, et al. Rituximab (IDEC-C2B8) and CVP chemotherapy in follicular or low grade B-cell lymphoma after relapse: Results after 6 months of follow up. Proc Am Soc Clin Oncol 2002;19:572.
10. Sacchi S, Tucci Amerli F. Phase II study with fludarabine and cyclophosphamide plus rituximab in relapsed follicular lymphoma patients. Blood 2002;100:572.
11. Hiddeman W, Forstpointer R, Fiedler F. The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone(FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular and mantle cell lymphoma. Blood 2001;98:844.
12. Cabanillas F, McLaughlin P, Hagemeister FB. Molecular responses with FMD plus rituximab chemoimmunotherapy for stage IV indolent follicular non-Hodgkins lymphoma. Blood 2000;96:331.
13. Hiddeman W, Kneba M, Dreyling M, Schmitz N, Lengfedler E, Schmits R, et al. Frontline therapy with rituximab added to the combination of CHOP significantly improves the outcome for patients with advanced stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low -Grade Lymphoma Study Group . Blood 2005;106:3725-32.
14. Dyer MJ. The role of Campath-1 antibodies in the treatment of lymphoid malignancies Semin Oncol 1999;26:52-7.
15. Faderl S, Thomas DA, O'Brien S. An exploratory study of the combination of monoclonal antibodies Campath- IH and rituximab in the treatment of CD-52 and CD20 positive chronic lymphoid disorders. Blood 2001;98:365.
16. Montillo M, Schinkoethe T, Etler T. Eradication of minimal residual disease with alemtuzumab in B-CLL patients:The need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest 2005;23:488-96.
17. Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G, et al. Results of alemtuzumab - based reduced intensity allogenic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006;107:1724-30.
18. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, et al. Targeting of the CD33-calcheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001;97:3197-204.
19. Tomblyn MR, Tallman MS. New developments in antibody therapy for AML. Semin Oncol 2003;30:502-8.
20. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce S A, Stefan H, et al. Experience with gemtuzumab ozogamicin and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002;99:4222-4.
21. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmaanouilides C, Joyce R, et al. Randomized controlled trial of yttrium 90 labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low grade, follicular or transformed B-cell non-Hodgkins lymphoma. J Clin Oncol 2002;20:2453-63.
22. Davies AJ. A review of tositumomab and I131 tositumomab radioimmunotherapy for the treatment of follicular lymphoma. Expert Opin Biol Ther 2005;5:577-88.
23. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131 Itositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-9.
24. Dillman RO. Perceptions of Herceptin: A monoclonal antibody for treatment of breast cancer. Cancer Biother Radiopharm 1999;14:5-10.
25. Wong SF. Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005;27:684-94.
26. Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. A J Health Sys Pharm 2005;62:1021-32.
27. Kabbinaver FF, Schulz J, McCleod M, Patel T, Hamm John T, Hecht R, et al. Addition of bevacizumab to bolus flurouracil and leucovorin in first line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23:3697-705.
28. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-40.
29. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughmann C, Greco A. Treatment of metastatic renal carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889-96.
30. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
31. Vectibix Package Insert Amgen USA
32. Werner RG. The development and production of biopharmaceuticals. Bioprocess International 2005;3:9.
33. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mandelson BS, et al. Phase I clinical study of pertuzumab, a novel Her dimerization inhibitor. In patients with advanced cancer. J Clin oncol 2005;23:2534-43.